Fang 2019.

Study name	Study on the effect of PRKCB1 modulating inflammatory factors and the role for developing major depressive disorder
Methods	Randomised placebo‐controlled trial
Participants	Participants: Drug‐naïve or medication‐free for no less than 4 weeks; 18 ‐ 60 years old, Han nationality; junior high school diploma or above; meeting the criteria of major depressive disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM)‐IV‐TR; Scored 17 or higher on the Hamilton's Depression Scale with 17 items (HAMD‐17) and scored 2 or higher for the 2nd item (depressive mood); Written informed consent has been obtained Aiming to enrol 350 participants
Interventions	Intervention: EPA ‐ 180 mg, DHA ‐ 120 mg, plus escitalopram ‐ 10 ‐ 20 mg/d Comparator: escitalopram ‐ 10 ‐ 20 mg/d
Outcomes	Primary: remission of acute phase (HDRS score of 7 or less) at week 12, remission of consolidate or maintenance phase (HDRS score of 7 or less) at 12 months
Starting date	January 2019
Contact information	Yiru Fang Fang, MD. PhD. Shanghai Mental Health Center, China
Notes	Clinical Trials: ID: NCT03899194